Hello world!

SynCell Biotechnology Inc. is here

SynCell News • May 18, 2020


he first quarter of April witnessed the born of SynCell Biotechnology Inc, a corporation that dreams with a future where antibiotic resistance is just a bad nightmare for humankind.

SynCell Biotechnology Inc. was born as the culprit of significant efforts from the original team and the many others who wanted the company’s idea to succeed: to bring bacterial-produced nanomaterials to market as potential biomedical agents to fight some of the most disturbing healthcare concerns, including bacterial infections and cancer control, among others.

A future where antimicrobial resistance (AMR) to antibiotics will be a minor problem

One of SynCell Biotechnology’s promises is a future where antimicrobial resistance (AMR) to antibiotics will be a minor problem. Unlike many other biotech companies, SynCell wants to tackle bacterial infections without the use of antibiotics, employing a solution that comes from within the problem: bacteria.

Behind the statement “bacteria evolve, but antibiotics do not, SynCell’s core was built around the idea of using the problem (bacteria) as a solution instead of looking for new antibiotic drugs that only boost the rise of AMR cases.

Therefore, SynCell uses pathogenic bacteria (those that are causing the disease) as a biofactory for the production of nanomaterials (materials with sizes below 100 nanometer) that will be used as efficient, environmentally friendly, cost-effective and tunable antimicrobial agents.

Bacteria evolve. Antibiotics do not.

The methods was named as a “Nanometric Trojan Horse (NTH)” approach by David Medina, one of the founders, and it allows to use the bacteria that you want to target to produce a nanoscale weapon that will induce the death of that same bacteria upon treatment.

Now, with a newly created company, the team is ready to start seeking funding and research opportunities to validate their technology. However, the path has not been easy.

The technology behind, invented and patented by David Medina and Prof. Thomas J. Webster, was taken outside of the lab at the end of Fall 2019. The team enrolled in the NSF-iCORPs program at Northeastern University with the aim to develop a suitable market and customer discovery strategies to bring the product to reality.

After a few months, hundreds of interviews and the spread of awareness among the scientific community, the company was created as a way to protect the identity and integrity of the technology and the idea, an idea whose mission is to bring SynCell Biotechnology to the front lines of the AMR race.